2026-01-02 - Analysis Report
Okay, here's a breakdown of the Starbucks (SBUX) data provided, along with analysis.

**1) Return Rate Comparison and Alpha/Beta Analysis:**

*   **Company Overview:** Starbucks Corp. is a global coffeehouse company and roaster of specialty coffees.
*   **Return Rate:** SBUX's cumulative return (-3.04%) significantly underperforms the S&P 500 (105.07%).
*   **Divergence:** The divergence between SBUX and VOO is currently at -108.1. The relative divergence is 3.9, indicating it's near the bottom of its historical divergence range.  This means the underperformance relative to the S&P 500 is substantial and near the worst it has been in the observed period.
*   **Alpha/Beta Analysis:**

    | Year       | CAGR    | MDD   | Alpha   | Beta | Cap(B) |
    |------------|---------|-------|---------|------|--------|
    | 2016-2018  | 6.0%    | 65.6% | -23.0%  | 0.8  | 73.2   |
    | 2017-2019  | 59.0%   | 80.5% | 18.0%   | 0.7  | 100.0  |
    | 2018-2020  | 88.0%   | 80.8% | 56.0%   | 1.0  | 121.7  |
    | 2019-2021  | 72.0%   | 80.8% | -4.0%   | 1.1  | 133.0  |
    | 2020-2022  | 17.0%   | 83.5% | -2.0%   | 1.1  | 112.8  |
    | 2021-2023  | -1.0%   | 83.5% | -29.0%  | 1.0  | 109.2  |
    | 2022-2024  | -7.0%   | 81.7% | -37.0%  | 1.0  | 103.8  |
    | 2023-2025  | -23.0%  | 81.7% | -91.0%  | 1.0  | 95.8   |

    *   **CAGR:** The Compounded Annual Growth Rate has declined significantly in recent periods, turning negative.
    *   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant price volatility and risk.
    *   **Alpha:** Alpha, representing risk-adjusted outperformance compared to a benchmark, is strongly negative, especially recently. This suggests significant underperformance relative to the market.
    *   **Beta:** Beta is around 1.0, indicating that SBUX's price tends to move in line with the market (S&P 500).
    *   **Cap(B):** Market capitalization has been decreasing.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 84.21
*   **Previous Close:** 85.25
*   **Change:** -1.22
*   **5-day SMA:** 84.936
*   **20-day SMA:** 85.2505
*   **60-day SMA:** 84.3198

    The stock price is currently below its 5-day and 20-day Simple Moving Averages (SMAs), suggesting potential short-term downward momentum.  The 60-day SMA is very close to the current price.

**3) RSI, PPO, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended).
*   **RSI:** 51.21 (Neutral - neither overbought nor oversold).
*   **PPO:** -0.1934 (Slightly negative, suggesting short-term weakness).
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (12 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)" - A buy signal based on the MRI.
*   **Recent (20 days) relative divergence change:** 1.6 (+): 단기상승 (Short-term rise).
*   **Price change:** The price decreased which may reflect the fluctuation issue (decline).
*   **Expected Return:** 0.0% (No expected excess return compared to the S&P 500 over the long term).

**4) Recent News & Significant Events:**

*   **Forbes (2025-12-15):**  Suggests a strategy of selling puts on SBUX, indicating a belief that the stock won't fall significantly below a certain price ($85).
*   **TipRanks (2025-12-30):**  Reports a slight slip in SBUX stock price despite a new MrBeast partnership.
*   **Meyka (2026-01-01):** Mentions buzz around Japan New Year menu and mobile promos.
*   **Yahoo Finance (2025-12-15):** Discusses valuation in light of leadership changes, barista strikes, and China expansion.
*   **The Motley Fool (2025-12-25):**  Highlights factors to watch in 2026, suggesting potential future growth drivers.
*   **Nasdaq (2025-12-13):**  Asks whether SBUX is an undervalued dividend stock for 2026.

**Analysis of News:** The news is a mix of potential opportunities (undervalued dividend stock, MrBeast partnership) and challenges (barista strikes, leadership overhaul).

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean rating of 2.36).
*   **Target Price:** Average: $94.13, High: $115.00, Low: $67.00
*   **Recent Rating Changes:** Not specified
  **Analysis of Analyst Opinions:** The analyst consensus leans towards "Buy", suggesting they believe the stock is currently undervalued. The average target price indicates potential upside from the current price.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-07-29 | 0.49  | 9.46 B$  |
| 2025-04-29 | 0.34  | 8.76 B$  |
| 2025-01-28 | 0.69  | 9.40 B$  |
| 2024-07-30 | 0.93  | 9.11 B$  |
| 2025-07-29 | 0.93  | 9.11 B$  |

*   **Trend:** Recent EPS has been lower than some of the previous quarters shown, despite relatively consistent revenue.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $9.57B  | 22.60%        |
| 2025-06-30 | $9.46B  | 22.80%        |
| 2025-03-31 | $8.76B  | 21.09%        |
| 2024-12-31 | $9.40B  | 24.49%        |
| 2024-09-30 | $9.07B  | 26.25%        |

*   **Trend:** Revenue has been relatively stable. Profit margins have decreased over the last five quarters.

**Capital and Profitability:**

| Quarter    | Equity     | ROE      |
|------------|------------|----------|
| 2025-09-30 | $-8.10B    | -1.65%   |
| 2025-06-30 | $-7.69B    | -7.26%   |
| 2025-03-31 | $-7.62B    | -5.04%   |
| 2024-12-31 | $-7.47B    | -10.45%  |
| 2024-09-30 | $-7.45B    | -12.21%  |

*   **Trend:** Negative equity and negative ROE indicate financial challenges. Although the values have been improving.

**7) Comprehensive Analysis:**

*   **Underperformance:** SBUX has significantly underperformed the S&P 500 recently. Its historical divergence is very high.
*   **Financial Health:** The company's financial information shows consistent revenue with decreasing profit margin. Additionally, SBUX has negative equity and ROE, which are significant concerns. However, they have been improving.
*   **Mixed Signals:** Technical indicators are mixed (neutral RSI, slightly negative PPO), but the MRI suggests a "High Investment Recommended." Analyst consensus is "Buy" with potential upside.
*   **News & Events:** Recent news highlights a mix of positive initiatives and ongoing challenges.
*   **Overall:** While analysts are generally positive and the MRI suggests a buy, the negative ROE, underperformance relative to the market, and decreasing profit margin should be considered. The potential upside from the analyst target prices might be attractive, but further investigation into the company's financials and future strategies would be prudent before making an investment decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.